What changed between these versions
A substantive expansion of the Stem Cell Therapeutic and Research Act of 2005. While Sections 1 and 2 remain substantively identical, v2 significantly modifies Section 3 to introduce new provisions for cord blood inventory management, unit transfer, and a definition for high-quality units, alongside extending appropriations. Additionally, v2 adds a new Section 4, establishing a periodic review of the state of science under the national program.
Overview
Extensive changes, primarily concentrated in the provisions related to cord blood inventory and the addition of a new review mechanism. · v2 significantly expands and clarifies the existing framework for cord blood inventory management and introduces a new requirement for periodic scientific review.
The most significant changes in v2 involve a comprehensive overhaul of the cord blood inventory provisions, shifting from a fixed numerical goal to a Secretary-determined "sufficient supply" and introducing mechanisms for unit transfer and active inventory management. A new definition for "high-quality cord blood unit" is also added. Furthermore, v2 introduces a new section requiring periodic review of the state of science under the national program, expanding its scope to include high-quality cord blood units and other emergent technologies. Sections 1 and 2, pertaining to the short title and reauthorization of the C.W. Bill Young Cell Transplantation Program, remain substantively identical to v1.
Major additions
This new subsection, titled "Transfer of Units," authorizes the Secretary to transfer cord blood units from banks that are no longer operational, do not meet clinical and quality standards, or fail to meet other requirements, to another qualified cord blood bank or approved entity.
This addition is crucial for safeguarding the existing inventory of cord blood units by providing a mechanism to prevent their loss or inaccessibility if a collecting bank becomes non-compliant or ceases operations. It ensures the continued availability of these critical resources for patients.
This new subsection, titled "Inventory Management," mandates the Secretary, in consultation with the Advisory Council on Blood Stem Cell Transplantation, to manage the National Cord Blood Inventory to maximize clinical utility, ensure genetic diversity, and promote efficient use of Federal resources. It also allows the Secretary to make determinations on continued storage and prioritize collection, retention, or disposition based on scientific and clinical evidence.
This provision establishes a strategic and dynamic approach to managing the cord blood inventory, moving beyond simple collection goals to active optimization based on evolving medical needs and scientific understanding. This could lead to more effective allocation of resources and better patient outcomes.
This new paragraph defines the term "high-quality cord blood unit" as a unit that meets current industry standards and requirements of the Food and Drug Administration.
This definition provides a clear, standardized benchmark for the quality of cord blood units, which is critical for clinical efficacy and patient safety. It underpins other modifications in v2 that refer to "high-quality" units.
This new section amends Section 379(o) of the Public Health Service Act to mandate a periodic review of the state of science regarding adult stem cells, high-quality cord blood units, and other emergent technologies. It sets a start date for this review and updates the reporting deadline.
This addition ensures that the national program remains current with scientific advancements and clinical best practices in the rapidly evolving field of regenerative medicine. It provides a mechanism for regular assessment and adaptation of policies.
Deletions
The phrase "in perpetuity or" was struck from the requirements for cord blood banks. This phrase likely pertained to the duration of storage agreements.
Removing this phrase grants more flexibility regarding the long-term storage commitments of cord blood banks, potentially allowing for more dynamic inventory management and disposition strategies, especially in light of the new inventory management provisions.
Modifications
This change shifts the focus from a fixed, quantitative target to a qualitative and adaptive goal, allowing the Secretary to adjust collection and inventory levels based on clinical demand, scientific advancements, and resource availability. This could lead to more efficient resource allocation and a more responsive inventory.
Before
The original text established an "inventory goal of at least 150,000 new units of high-quality cord blood."
After
The amended text changes the goal to "a sufficient supply, as determined by the Secretary, of high-quality cord blood units."
Cord blood banks will now be explicitly required to agree to the terms governing the transfer of units in cases of non-compliance or cessation of operations, directly linking their agreements to the new inventory protection mechanism.
Before
The original text for paragraph (5) (not explicitly provided in v1, but implied to be replaced) would have contained different terms for cord blood bank agreements.
After
The amended text requires cord blood banks to "agree to the terms described in subsection (e)."
Decisions regarding extensions will now also consider the criteria outlined in paragraph (4), which has been updated to emphasize "available scientific and clinical evidence" and "applicable clinical and quality standards." This broadens the considerations for granting extensions.
Before
The original text referred to "paragraph (2)" in relation to extensions.
After
The amended text refers to "paragraphs (2) and (4)."
Decisions on cord blood unit collection and availability will now be informed by a more comprehensive body of evidence, including clinical outcomes, and will be held to stricter quality and clinical standards, potentially improving the utility and safety of the units.
Before
The heading was "science," and the text referred to using "the best scientific information available in order to maximize the number of cord blood units available."
After
The heading is changed to "available scientific and clinical evidence," and the text refers to using "current scientific and clinical information in order to maximize the availability of high-quality cord blood units meeting applicable clinical and quality standards."
Ensures continued federal funding for the cord blood inventory program for an additional five fiscal years (FY2027-FY2031), providing financial stability for its operations and long-term planning.
Before
The authorization of appropriations was for "2022 through 2026."
After
The authorization of appropriations is for "2027 through 2031."
Establishes a clear and definite timeline for when the periodic review of the state of science must begin, ensuring accountability and timely initiation of the review process for the national program.
Before
The original text stated "Not less" regarding the frequency of review.
After
The amended text adds "Beginning 1 year after the date of enactment of the Stem Cell Therapeutic and Research Reauthorization Act of 2026, not less" before "Not less."
The review process will now comprehensively cover high-quality cord blood units and other emerging technologies in addition to adult stem cells and birthing tissues, ensuring that the national program's policies and practices remain informed by the latest scientific and technological advancements across the broader field.
Before
The original text referred to "adult stem cells and birthing tissues" as subjects of review.
After
The amended text expands the subjects to include "adult stem cells, high-quality cord blood units (as defined in section 2(h) of the Stem Cell Therapeutic and Research Act of 2005), and other emergent technologies."
Aligns the reporting deadline with the enactment of the reauthorization act, providing a new, consistent timeframe for the submission of the initial review report, ensuring its relevance to the updated legislation.
Before
The original deadline for the initial report was "June 30, 2025."
After
The amended deadline is "3 years after the date of enactment of the Stem Cell Therapeutic and Research Reauthorization Act of 2026."
Scope
Meaningful expansion or narrowing — Changes are concentrated in the provisions related to cord blood inventory management (Section 3) and the addition of a new section for periodic scientific review (Section 4). Sections 1 and 2 remain substantively unchanged. — v2 represents a meaningful expansion and clarification of policy, particularly in shifting cord blood inventory management from a fixed numerical goal to a more dynamic, Secretary-determined "sufficient supply" and introducing proactive measures for unit transfer and strategic inventory management. It also broadens the scope and formalizes the periodic review of scientific advancements. — The new definition of "high-quality cord blood unit" (Section 3(6)(B)) interacts with and clarifies other provisions in Section 3 and Section 4 that refer to such units. The new transfer of units provision (Section 3(5) new (e)) also interacts with the requirements for cord blood banks, and the new periodic review section (Section 4) expands the scope of an existing review mechanism.
Impact analysis
Cord blood banks participating in the National Cord Blood Inventory program.
Procedural change, with increased oversight and accountability, but also potentially more flexible long-term storage options.
They are now subject to new requirements regarding the transfer of units if they become non-operational or non-compliant, and their agreements must align with these new terms. The specific "in perpetuity or" storage term has been removed, potentially offering more flexibility.
Patients and researchers relying on the National Cord Blood Inventory.
Gain, through potentially improved access to higher quality and more diverse cord blood units.
The inventory will be managed more strategically for clinical utility and genetic diversity, and units from non-compliant banks can be transferred to ensure continued availability. The definition of "high-quality" is standardized, aiming for better quality control.
The Secretary of Health and Human Services and the Advisory Council on Blood Stem Cell Transplantation.
Procedural change, with increased responsibilities and discretion.
The Secretary is granted expanded authority and responsibility for determining a "sufficient supply" of cord blood, managing the inventory strategically, transferring units, and conducting periodic scientific reviews. The Advisory Council will be consulted on inventory management.
The scientific and medical community involved in stem cell and regenerative medicine.
Procedural change, with enhanced integration of scientific and clinical advancements into program policy.
The periodic review of the state of science will now explicitly include high-quality cord blood units and other emergent technologies, ensuring that program policies are regularly updated based on the latest evidence and broader technological advancements.